Physiologas, a Home Hemodialysis Company, Secures Funding from Toyota Coniq Corporation
Physiologas Technologies Inc. has completed the third close of its Series A funding round, securing investment from Toyota Coniq Corporation. This funding will accelerate the development of home hemodialysis products aimed at improving the quality of life for end-stage renal disease patients and their families.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 18:00
Physiologas Technologies Inc. (Headquarters: Sagamihara City, Kanagawa Prefecture; Representative Director: Kazuyoshi Miyawaki; hereinafter referred to as "the Company") is pleased to announce that it has completed the third close of its Series A funding round by the end of March 2026.
In this round, a third-party allotment of shares was implemented with Toyota Coniq Corporation as a new subscriber.
The funds raised will be utilized for the design, development, prototyping, and non-clinical trials (electrical safety tests, electromagnetic compatibility tests, biological safety tests, etc.) of home hemodialysis devices and consumables.
Please refer to here for the press release by Toyota Coniq Corporation.
About Home Hemodialysis
Clinic-based hemodialysis treatment is a time-consuming and physically demanding treatment method, with 340,000 end-stage renal disease patients in Japan typically receiving it for 4 hours, three times a week. On the other hand, home hemodialysis treatment is known as a treatment method that offers a higher quality of life for patients and a better prognosis, as it eliminates the need for hospital visits and allows for frequent treatments.
However, in Japan, home hemodialysis is not widely adopted, with only about 800 patients. This is because there are no dialysis devices developed specifically for home use, requiring patients to install large machines used in clinics that require water supply and drainage piping, as well as complex operations such as water quality management and alarm response.
About Our Project
Based on the research results of Kenichi Kokubo (Associate Professor, Kitasato University School of Allied Health Sciences, and CTO of the Company), the Company is developing a small, safe home-use hemodialysis device by commercializing a mechanism that recirculates dialysate within the device by adsorbing and removing uremic toxins.
The introduction of our developed product is expected to lead to a high life prognosis in clinical terms, as it eliminates the need for hospital visits and enables frequent dialysis. Furthermore, by improving the QOL of patients and their families, it is anticipated to have a social impact, promoting the social reintegration and employment of end-stage renal disease patients, and is expected to have high economic utility.
About Physiologas Technologies Inc.
Physiologas Technologies Inc. is a startup originating from Kitasato University, established in 2020 with the purpose of "innovating healthcare with technology to deliver happier lives to patients and their families."
|
Company Name |
Physiologas Technologies Inc. |
|
Location |
1-15-1 Kitasato, Minami-ku, Sagamihara City, Kanagawa Prefecture (within Kitasato University Sagamihara Campus) |
|
Establishment |
March 2020 |
|
Capital |
332,143,825 JPY (as of March 31, 2026) |
|
Business Activities |
Development, manufacturing, and sales of medical devices (home hemodialysis devices) |
|
URL |
Contact for this matter
Physiologas Technologies Inc. Public Relations
FAQ
What is Physiologas Technologies developing?
They are developing small, safe home-use hemodialysis devices and consumables. They have commercialized a system that adsorbs and removes uremic toxins and recirculates dialysate.
What is the purpose of this funding round?
The funds will be used for the design, development, prototyping, and non-clinical trials (electrical safety, electromagnetic compatibility, biological safety, etc.) of home hemodialysis devices and consumables.
Why is home hemodialysis not widespread in Japan?
This is because there are no dialysis devices developed specifically for home use in Japan, requiring patients to install large, complex machines designed for clinics in their homes.